SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Huntsman Cancer Institute, Fred Hutch Cancer Center, U-M Rogel Cancer Center, University of California Davis Medical Center, University of Iowa, Northwestern University, University of Southern California, USC Norris Comprehensive Cancer Center, Comprehensive Cancer Centers of Nevada, The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4232606715